The point is valid that the company would be ahead with a takeover or alliance with someone with a major distribution capability. I certainly hope that the "second or third" largest medical supply company in the world will play this role as NanoLogix works to resolve one of its problems with the N-Assay technology. I am also pleased that we have seen it suggested that Flatpak revenues are supporting our investment and keeping the company in the black operationally. Like all serious and honest investors (and I admit I don't see Ray as one) I want to see the N-Assay paper published, the potentially great capabilities of the federal research process turn into $$, expanding sales of the Flatpak, and a serious endorsement or buyout by the mega-company. That is what we are waiting around to see so I'm simply "riding the wave".